The AGM approved the Board's proposal to give the Board the authorisation to issue, with or without preferential right, a maximum of 6,000,000 new shares. This may be done at one or more occasions and shall be made at the then prevailing share price.
Meeting agenda items submitted by the Swedish Association of Share Investors for decisions regarding the Nomination Committee, Remuneration Committee and Audit Committee were resolved as follows:
In the nomination process for members of the Company's Board of Directors, the three largest shareholders in the Company each appoint one representative during the fourth quarter of the year; under management by the Chairman of the Board, the representatives formulate a proposal that is submitted to the Board for a final decision by the Annual General Meeting. The names of the three representatives shall be announced as soon as they are appointed.
With regard to a remuneration committee, such issues shall be addressed by the entire Board of Directors. Similarly, audit issues shall be addressed by the entire Board of Directors.
Board members Sven Andréasson, Mats Arnhög, Maria Borelius, Professor Klas Kärre, Peter Sjöstrand and Peter Ström were re-elected by the Annual General Meeting. Mats Arnhög will continue serving as Chairman of the Board.
Sven Andréasson's address to shareholders at the Annual General Meeting (and the Annual Report) will be available in its entirety at www.activebiotech.com.
Lund, April 22, 2004
Active Biotech AB
Sven Andréasson
President & CEO
Active Biotech
AB is a biotechnology company focusing on research in and development of pharmaceuticals. Active Biotech has a strong R&D portfolio and pipeline products with focus primarily on autoimmune/inflammatory diseases and cancer. Most advanced projects include orally administered small molecules with unique immunomodulatory properties that can be used to treat autoimmune and inflammatory diseases (SAIK), as well as a novel concept for use in cancer immunotherapy (TTS).
Active Biotech AB
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 20 50